CORD-19:0036b28fddf7e93da0970303672934ea2f9944e7 / 82082-82238 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T621","span":{"begin":0,"end":156},"obj":"Sentence"},{"id":"T58316","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to the conventional therapy results in significant reduction in GV."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T357","span":{"begin":15,"end":32},"obj":"Disease"},{"id":"T358","span":{"begin":34,"end":36},"obj":"Disease"},{"id":"T79260","span":{"begin":15,"end":32},"obj":"Disease"},{"id":"T354","span":{"begin":34,"end":36},"obj":"Disease"}],"attributes":[{"id":"A357","pred":"mondo_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A358","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A359","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0016367"},{"id":"A38269","pred":"mondo_id","subj":"T79260","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A47353","pred":"mondo_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A23130","pred":"mondo_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/MONDO_0016367"}],"text":"In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to the conventional therapy results in significant reduction in GV."}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T271","span":{"begin":15,"end":32},"obj":"Phenotype"},{"id":"T272","span":{"begin":34,"end":36},"obj":"Phenotype"}],"attributes":[{"id":"A271","pred":"hp_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A272","pred":"hp_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/HP_0000819"}],"text":"In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to the conventional therapy results in significant reduction in GV."}